R. Mondola, S. Magara, A. Eramo, A. De Bartolomeis - Vol. 10, September 2004, Issue 3
Testo Bibliografia Summary Indice
Terapia di potenziamento degli antipsicotici con farmaci
non convenzionali nel trattamento della schizofrenia
Augmentation therapy of antipsychotics by no conventional drugs in
schizophrenia treatment
1 Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
2 Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
3 Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
4 Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
5 Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241-53.
6 Cotman CW, Monaghan DT. Chemistry and anatomy of excitatory amino acid systems. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press 1987, pp. 451-457.
7 Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12:1-13.
8 Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-36.
9 Ulas J, Cotman CW. Excitatory amino acid receptors in schizophrenia. Schizophr Bull 1993;19:105-17.
10 D’Souza DC, Charney DS, Krystal JH. Glycine site agonist of the NMDA receptor: a review. CNS Drug Review 1:227-260.
11 Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-31.
12 Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988;241:835-7.
13 Lenhninger AL. Principles of Biochemistry. New York, NY: Worth Publishers Inc 1982:535-641.
14 Peterson SL. Diazepam potentiation by glycine in pentylenetetrazol seizure is antagonized by 7-chlorokynuretic acid. Pharmacol Biochem Behav 1994;47:241-6.
15 Toth E, Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 1986;11:393-400.
16 Potkin SG, Costa J, Roy S, Sramek J, Gulasekram B. Glycine in the treatment of schizophrenia: theory and preliminary results. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press 1992:171-7.
17 Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-6.
18 Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, Calif: Soc Behav Sci 1987.
19 Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36.
20 Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999;156:145-7.
21 Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000;157:826-8.
22 Hanngren H, Hansson E, Ullberg S. An autoradiographic study of the distribution of tritium-labeled cycloserine in mice. Antibiot Chemother 1961;12:46-54.
23 Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-5.
24 Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:1628-30.
25 Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-7.
26 Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994;14:4159-66.
27 Goff DC, Tsai G, Beal MF, Coyle JT. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry 1995;152:1730-6.
28 Fletcher EJ, MacDonald JF. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol 1993;235:291-5.
29 Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport 1995;6:2500-4.
30 McCoy L, Richfield EK. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 1996;213:137-41.
31 Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002;159:480-2.
32 Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-9.
33 Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002;56:19-23.
34 Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999;45:512-4.
35 Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997;283:226-34.
36 Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, Cozzi A, et al. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 2001;6:380-6.
37 Polese D, Serpis AA, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Homer1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 2002;27:906-13.
38 Hashimoto A, Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 1997;52:325-53.
39 Contreras PC. D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 1990;29:291-3.
40 Tanii Y, Nishikawa T, Hashimoto A, Takahashi K. Stereoselective inhibition by D- and L-alanine of phencyclidine-induced locomotor stimulation in the rat. Brain Res 1991;563:281-4.
41 Tanii Y, Nishikawa T, Hashimoto A, Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 1994;269:1040-8.
42 Iwama H, Takahashi K, Kure S, Hayashi F, Narisawa K, Tada K, et al. Depletion of cerebral D-serine in non-ketotic hyperglycinemia: possible involvement of glycine cleavage system in control of endogenous D-serine. Biochem Biophys Res Commun 1997;231:793-6.
43 Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-5.
44 Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 1998;95:15730-4.
45 Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003;89:691-703.
46 Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-6.
47 Bergeron F, Otto A, Blache P, Day R, Denoroy L, Brandsch R, et al. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur J Biochem 1998;257:556-61.
48 Ugedo L, Grenhoff J, Svensson TH. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989;98:45-50.
49 Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
50 Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 1995;676:157-68.
51 Arvanov VL, Wang RY. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 1998;18:197-209.
52 Silver H, Blacker M, Weller MP, Lerer B. Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 1989;25:502-4.
53 Bacher NM, Sanzone MM, Kaup B. Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine. J Clin Psychopharmacol 1994;14:424-5.
54 Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1995;10:67-72.
55 Silver H, Blacker M, Weller MP, Lerer B. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Biol Psychiatry 1991;30:523-5.
56 Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451-5.
57 Chaudhry IB, Soni SD, Hellewell JS, Deakin JF. Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. Schizophr Res 2002;53:17-24.
58 Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 1999;24:49-52.
59 Kalkman HO, Loetscher E. Alpha(2C)-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 2003;462:33-40.
60 Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345:557-62.
61 Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151-63.
62 Hertel P, Fagerquist MV, Svensson TH. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by a2 adrenoceptor blockade. Science 1999;286:105-7.
63 Hertel P, Nomikos GG, Svensson TH. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur J Pharmacol 1999;371:153-8.
64 Litman RE, Hong WW, Weissman EM, Tung-Ping S, Potter WZ, Pickar D. Idazoxan, an a2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 1993;13:264-7.
65 Oyewumi LK, Vollick D, Merskey H, Plumb C. Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 1994;19:145-50.
66 Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996;19:341-8.
67 Prast H, Tran MH, Fischer H, Kraus M, Lamberti C, Grass K, et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;360:558-64.
68 Prast H, Tran MH, Lamberti C, Fischer H, Kraus M, Grass K, et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H1 and H2 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;360:552-7.
69 Prast H, Grass K, Philippu A. Influence of histamine receptor agonists and antagonists on ultradian rhythm of EEG in the posterior hypothalamus of the rat. Neurosci Lett 1996;216:21-4.
70 Rosse RB, Kendrick K, Tsui LC, Fay-McCarthy M, Collins JP Jr, Rosenberg P, et al. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacol 1995;18:369-74.
71 Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins JP Jr, Wyatt RJ. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993;16:518-24.
72 Rapaport MH, Muller N. Immunological states associated with schizophrenia. In: Arder R, Felten DL, Choen N, eds. Psychoneuroimmunology, 3° ed. San Diego, Calif: Academic Press 2001, pp. 373-382.
73 Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995;8:131-45.
74 Korschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Muller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 1996;19:103-9.
75 Muller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implication for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
76 Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:75-83.
77 Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993;150:1408-10.
78 McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-7.
79 Muller N, Empl M, Riedel M, Schwarz M, Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997;247:308-13.
80 Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15.
81 Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995;29:141-52.
82 Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-34.
83 van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and behavioural measures in schizophrenia. In: Wieselmann G, ed. Current Update in Psychoimmunology. New York: Springer 1997:51-5.
84 Muller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999;156:634-6.
85 Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Pepper JR, Mitchell JA. Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998;249:44-7.
86 Schwarz MJ, Riedel M, Ackenheil M, Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 2000;47:29-33.
87 Schwarz MJ, Ackenheil M, Riedel M, Muller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998;253:201-3.
88 Muller N, Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 1995;14:223-8.
89 McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer’s disease. Drugs Aging 2000;17:1-11.
90 Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997;17:2746-55.
91 Hewett SJ, Uliasz TF, Vidwans AS, Hewett JA. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 2000;293:417-25.
92 Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-86.
93 Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996;713:64-9.
94 Yermakova A, O’Banion MK. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 2000;6:1755-76.
95 Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999;843:118-29.
96 Carlsson A. Schizophrenie und Neurotransmitter-Strörungen: neue Perspektiven und therapeutische Ansätze. In: Möller HJ, Müller N, eds. Moderne Konzepte zu Diagnostik, Pathogenese und Therapie der Schiziphrenie. New York: Springer-Verlag 1998, pp. 93-116.
97 Tyrer P. Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 1976;128:354-60.
98 Cole JO, Jones RT, Klerman GL. Drug therapy. Prog Neurol Psychiatry 1961;16:539-74.
99 Kamman GR, Freeman JG, Lucero R. The effect of iproniazid on the behavior of long-term mental patients. J Nerv Ment Dis 1953;118:391-407.
100 Bucci L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 1987;91:104-8.
101 Siris SG, van Kammen DP, Docherty JP. Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 1978;35:1368-77.
102 Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 1996;184:295-301.
103 Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry 1999;40:148-50.
104 Yu PH. Pharmacological and clinical implications of MAO-B inhibitors. Gen Pharmacol 1994;25:1527-39.
105 Mackay AV. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980;137:379-83.
106 van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 1986;43:978-83.
107 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
108 Stein L, Wise CD. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 1971;171:1032-6.
109 Rosen J, Silk KR, Rice HE, Smith CB. Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study. Biol Psychiatry 1985;20:539-45.
110 Murray RM, Lewis SM, Reveley AM. Towards an etiological classification of schizophrenia. Lancet 1985;1:1023-6.
111 Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989;46:745-53.
112 Bowers MB Jr. Lumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes. J Nerv Ment Dis 1974;158:325-30.
113 Post RM, Fink E, Carpenter WT Jr, Goodwin FK. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975;32:1063-9.
114 Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study. J Clin Psychopharmacol 1999;19:522-5.
115 Zhang AZ, Zhou GZ, Xi GF, Gu NF, Xia ZY, Yao JL, et al. Lower CSF level of dynorphin (1-8) immunoreactivity in schizophrenic patients. Neuropeptides 1985;5:553-6.
116 Hollt V. Precursors of opioid peptides and their gene regulation. Clin Neuropharmacol 1992;15(Suppl 1):50A-51A.
117 Lindstrom LH, Terenius L, Nyberg F. Opioid peptides in psychiatric disorders. Clin Neuropharmacol 1992;15(Suppl 1):58A-59A.
118 Renlund S, Erlandsson I, Hellman U, Silberring J, Wernstedt C, Lindstrom L, et al. Micropurification and amino acid sequence of beta-casomorphin-8 in milk from a woman with postpartum psychosis. Peptides 1993;14:1125-32.
119 Gil-Ad I, Dickerman Z, Amdursky S, Laron Z. Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects. Psychopharmacology 1986;88:496-9.
120 Wiegant VM, Verhoef CJ, Burbach JP, de Wied D. Increased concentration of alpha- and gamma-endorphin in post mortem hypothalamic tissue of schizophrenic patients. Life Sci 1988;42:1733-42.
121 Smith MA, Nemeroff CB. Behavioral effects of brain peptides. In: Collu R, Brown GM, Van Loo GR, eds. Clinical Neuroendocrinology. Boston: Blackwell 1988:189-234.
122 Pickar D, Bunney WE Jr, Douillet P, Sethi BB, Sharma M, Vartanian ME, et al. Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study. Biol Psychiatry 1989;25:440-8.
123 Ragheb M, Berney S, Ban T. Naltrexone in chronic schizophrenia. Results of a clinical trial. Int Pharmacopsychiatry 1980;15:1-5.
124 Gitlin MJ, Gerner RH, Rosenblatt M. Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology 1981;74:51-3.
125 Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
126 Ernst M, Devi L, Silva RR, Gonzalez NM, Small AM, Malone RP, et al. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221-7.
127 Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32:1283-91.
128 Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. The therapeutic role of naltrexone in negative symptom schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1239-49.
129 Manchanda R, Hirsch SR. Rating scales for clinical studies on schizophrenia. In: Bradley PB, Hirsch SR, eds. The Psychopharmacology and Treatment of schizophrenia. Oxford: Oxford University Press 1986, pp. 234-262.
130 Calenco-Choukroun G, Dauge V, Gacel G, Roques BP. Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-opioid receptor agonist. Eur J Pharmacol 1991;209:267-71.
131 Lindenmayer JP, Gardner E, Goldberg E, Opler LA, Kay SR, van Praag HM, et al. High-dose naloxone in tardive dyskinesia. Psychiatry Res 1988;26:19-28.
132 Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 1998;18:248-51.
133 Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia Schizophr Res 1998;30:193-208.
134 Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991;48:563-8.
135 Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 1991;48:578.
136 Glen AI, Glen EM, Horrobin DF, Vaddadi K, Spellman M, Morse Fisher N, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994;12:53-61.
137 Glen AI, Cooper SJ, Rybakowski J, Vaddadi K, Brayshaw N, Horrobin DF. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996;55:9-15.
138 Yao JK. Red blood cell and platelet fatty acid metabolism in schizophrenia. In: Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in schizophrenia. Carnforth, UK: Marius Press 1999, pp. 57-74.
139 Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000;42:7-17.
140 Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch Gen Psychiatry 1997;54:487-94.
141 Ross BM. Brain and blood phospholipase activity in psychiatric disorders. In: Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press 1999, pp. 23-29.
142 Gattaz WF, Hubner CK, Nevalainen TJ, Thuren T, Kinnimen PKJ. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 1990;28:495-501.
143 Gattaz WF, Schmitt A, Maras AM. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 1995;16:1-6.
144 Finnen MJ, Lovell CR. Purification and characterisation of phospholipase A2 from human epidermis. Biochem Soc Trans 1991;19:91S.
145 Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7-18.
146 Thomas EA, Danielson PE, Nelson PA, Pribyl TM, Hilbush BS, Hasel KW, et al. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J Neurochem 2001;76:789-96.
147 McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
148 Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in middle-aged Japanese men. Eur J Clin Nutr 2001;55:643-50.
149 Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr Res 1995;18:85-6.
150 Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-4.
151 Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49:243-51.
152 Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133-41.
153 Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-93.